Adult-onset autoimmune neutropenia (AIN) is rarely self-limiting, unlike infant-onset AIN. Although several therapeutic agents have been reported, including corticosteroids, more effective treatment options may exist. Here, we describe neutrophil recovery by eltrombopag in a 52-year-old male AIN patient with immune thrombocytopenia (ITP) who was referred to our hospital with severe neutropenia. Within a year of referral, he developed moderate thrombocytopenia. He was diagnosed with AIN and concurrent ITP, based on the detection of antineutrophil antibodies and bone marrow aspiration, respectively. Further platelet count reduction and the appearance of purpura prompted an initial treatment of 0.5 mg/kg prednisolone. Thrombocytopenia remission was prompt but transient, with platelet counts rapidly declining before initiating prednisolone tapering. Similarly, absolute neutrophil counts (ANCs), after a shorter recovery period, returned to the baseline level below 2×10/l. Further platelet reduction was prevented by eltrombopag administration. Intriguingly, the ANCs recovered following platelet recovery and remained above 5×10/l for > three months despite prednisolone dosage tapering. To our knowledge, this is the first report describing the effectiveness of eltrombopag in AIN.

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.59.310DOI Listing

Publication Analysis

Top Keywords

recovery eltrombopag
8
adult-onset autoimmune
8
autoimmune neutropenia
8
ain
5
[neutrophil recovery
4
eltrombopag
4
eltrombopag treatment
4
treatment patient
4
patient adult-onset
4
neutropenia immune
4

Similar Publications

Introduction: Thrombocytopenia is a common clinical problem in cancer patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). It can occur as prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) and may cause potentially fatal bleeding. However, data on the treatment of post-transplant thrombocytopenia is still lacking.

View Article and Find Full Text PDF
Article Synopsis
  • This study focuses on chronic immune thrombocytopenic purpura (ITP) in children, reporting on epidemiological data and clinical management from a pediatric department in southern Tunisia over 13 years.
  • Out of 72 newly diagnosed ITP cases, 11 evolved into chronic ITP, with a mix of symptoms and complications, including two patients who experienced severe cases requiring advanced treatment.
  • The findings highlight the difficulties pediatricians face in managing chronic ITP, emphasizing the importance of existing guidelines to assist in treatment strategies for severe cases.
View Article and Find Full Text PDF

Hematopoietic cell transplantation (HCT) is a well-established procedure that has become a therapeutic mainstay for various hematological conditions. Prolonged thrombocytopenia following HCT is associated with a significant risk of morbidity and mortality, yet no universally recognized treatment protocol exists for such a complication. First-generation thrombopoietin receptor (TpoR) agonists as well as second-generation agents are known for their role in enhancing platelet production, and their use is expanding across various thrombocytopenic conditions.

View Article and Find Full Text PDF
Article Synopsis
  • A 74-year-old man with severe aplastic anaemia achieved a long-term remission due to the growth of HLA allele-deficient clones, despite initial treatment complications.
  • After starting eltrombopag and ciclosporin, his blood counts eventually normalized over a span of 3 years, showing a complete recovery of blood cell production.
  • Research techniques like flow cytometry and deep sequencing indicated that his recovery relied on clones with mutations that interfered with antigen presentation, demonstrating a potential new approach for managing immune-related aplastic anaemia in similar patients.
View Article and Find Full Text PDF

First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.

Bone Marrow Transplant

October 2024

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

Matched-related donor hematopoietic stem cell transplantation (HSCT) remains the preferred first-line option for severe aplastic anemia (SAA) patients aged <40 years even in the era of eltrombopag (EPAG). However, there has not been any direct comparison between immunosuppressive therapy (IST) plus EPAG (IST + EPAG) and haploidentical HSCT (Haplo-HSCT) as first-line therapy. This study prospectively compared the efficacy, safety and health-related quality of life (HRQoL) of Haplo-HSCT (n = 147) and IST + EPAG (n = 121) as first-line treatment for patients with SAA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!